Keeping up with the rules for peptides is a bit like trying to read a map that is constantly being redrawn. As of late 2026, the FDA has been busy moving things around, which changes what your local compounding pharmacy can actually do.
The BPC-157 and KPV status shift
If you have been following BPC-157, the regulatory ground has shifted under its feet. It was previously placed in FDA Category 2, a group for substances that might present significant safety risks. The FDA's Pharmacy Compounding Advisory Committee reviewed it in July 2026 to see if it belongs on the 503A Bulks List—the list of ingredients doctors can legally use for custom-made patient prescriptions.
The agency has raised some eyebrows regarding its safety. They have pointed out concerns like immunogenicity (when your body’s immune system reacts to a drug) and a general lack of human safety data.
Similarly, the peptide KPV was also moved out of Category 2 after its nomination was withdrawn. Like its cousins, its future was discussed by the advisory committee in July 2026. For now, the FDA still notes that there is very limited information on how humans react to it.
Why are some peptides being restricted?
It turns out the government is a big fan of data, and many peptides currently lack it. Several well-known compounds are currently listed in Category 2 due to safety or "immunogenicity" concerns. This list includes:
- GHRP-2 and GHRP-6
- Melanotan II (which has had multiple serious adverse event reports)
- LL-37
- PEG-MGF
- MK-677
The news on Semaglutide
Semaglutide is already FDA-approved (you might know it as Wegovy or Ozempic), but the rules for making custom versions are changing. Because the national shortage has ended, pharmacies are back to strict rules against making "essentially copies" of the approved drugs.
We also have a mountain of safety data from the FAERS (the FDA's system for reporting side effects). While it helped participants lose 14.9% of their body weight in the STEP 1 trial, it also has some documented quirks.
Common side effects in the label include:
- Nausea and vomiting
- Delayed gastric emptying (when food stays in your stomach too long)
- Pancreatitis (inflammation of the pancreas)
Some newer things have popped up too. The FDA added pulmonary aspiration (when food or liquid gets into the lungs) to the label in 2025 because of risks during general anesthesia. There is also an emerging signal for NAION, an eye condition, which was under review by European regulators as of January 2025.
What do you do with this info?
This is a great one to bring up with your doctor. If you are looking for guidance on these regulatory shifts, you can find peptide-experienced physicians in our Find a Doctor directory. Navigating these updates is much easier with a professional.
If you want to explore what is available locally, check out our peptide therapy near me resource to see your options. A qualified peptide doctor can help you understand which options are currently compliant with these 2026 rules.
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.